IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
|
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [1] The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
    Antonio Ceriello
    Valeria De Nigris
    Hiroaki Iijima
    Takahiro Matsui
    Maki Gouda
    Drugs, 2019, 79 : 733 - 750
  • [2] The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
    Ceriello, Antonio
    De Nigris, Valeria
    Iijima, Hiroaki
    Matsui, Takahiro
    Gouda, Maki
    DRUGS, 2019, 79 (07) : 733 - 750
  • [3] Characteristics and Clinical Implications of the Pharmacokinetic Profile of Ibuprofen in Patients with Knee Osteoarthritis
    L. Gallelli
    O. Galasso
    A. Urzino
    S. Saccà
    D. Falcone
    C. Palleria
    P. Longo
    A. Corigliano
    R. Terracciano
    R. Savino
    G. Gasparini
    G. De Sarro
    S. R. Southworth
    Clinical Drug Investigation, 2012, 32 : 827 - 833
  • [4] Characteristics and Clinical Implications of the Pharmacokinetic Profile of Ibuprofen in Patients with Knee Osteoarthritis
    Gallelli, L.
    Galasso, O.
    Urzino, A.
    Sacca, S.
    Falcone, D.
    Palleria, C.
    Longo, P.
    Corigliano, A.
    Terracciano, R.
    Savino, R.
    Gasparini, G.
    De Sarro, G.
    Southworth, S. R.
    CLINICAL DRUG INVESTIGATION, 2012, 32 (12) : 827 - 833
  • [5] Pharmacokinetic profile of cefaclor
    Sourgens, H
    Derendorf, H
    Schifferer, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (09) : 374 - 380
  • [6] PHARMACOKINETIC PROFILE OF RISPERIDONE
    BORISON, RL
    DIAMOND, BI
    MEIBACH, RC
    NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) : S112 - S113
  • [7] Pharmacokinetic profile of iobitridol
    Dencausse, A
    Violas, X
    Feldman, H
    Havard, P
    Chambon, C
    ACTA RADIOLOGICA, 1996, 37 : 25 - 34
  • [8] Pharmacokinetic Profile of Dexloxiglumide
    Stefano Persiani
    Massimo D’Amato
    Abhijeet Jakate
    Partha Roy
    Julie Wangsa
    Ram Kapil
    Lucio C. Rovati
    Clinical Pharmacokinetics, 2006, 45 : 1177 - 1188
  • [9] Pharmacokinetic profile of fesoterodine
    Malhotra, B.
    Guan, Z.
    Wood, N.
    Gandelman, K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (11) : 556 - 563
  • [10] Pharmacokinetic profile of dexloxiglumide
    Persiani, Stefano
    D'Amato, Massimo
    Jakate, Abhijeet
    Roy, Partha
    Wangsa, Julie
    Kapil, Ram
    Rovati, Lucio C.
    CLINICAL PHARMACOKINETICS, 2006, 45 (12) : 1177 - 1188